Symposium on Malignant Skin Inflammation
Wednesday, November 15, 2023
Primary cutaneous lymphomas, often pose diagnostic challenges due to their resemblance to benign inflammatory skin diseases. We are dedicating this symposium to this topic and are proud to present an excellent group of international leaders in the field, who will present their data and opinion on the role of inflammation in primary cutaneous lymphomas. We will also reserve spots for abstract submitters who want to present their data at this new symposium.
Explore primary cutaneous lymphomas at the inaugural Symposium on Malignant Skin Inflammation. Learn from experts about the role of inflammatory processes and the malignant clone in this rare form of skin cancer. Connect with top researchers and stay informed about the latest discoveries in the field.
|Welcome address organizing committee
|MALIGNANT INFLAMMATION – ROLE OF INFECTIONS AND ENVIRONMENTAL DRIVERS
|Keynote lecture: Bacteria fuel malignant inflammation and disease activity in CTCL
|Niels Ødum, Copenhagen, Denmark
|Microbial triggers and clonal evolution in CTCL pathogenesis
|Sergei Koralov, New York, NY, USA
|Chronic T cell activation by CD1a and Staphylococcal lipids
|Annemieke de Jong, New York, NY, USA
|AhR signaling drives defective type I IFN signaling in mycosis fungoides
|Rachael Clark, Boston, MA, USA
|Infectious and environmental drivers of CTCL
|Larisa Geskin, New York, NY, USA
|ROLE OF THE MICROENVIRONMENT
|The micromilieu in CTCL: From inflammation over tumor progress to antitumoral response
Gabor Dobos, Berlin, Germany
|Targeting immunosuppressive macrophages in the tumor microenvironment of CTCL
|Christiane Querfeld, Duarte, CA, USA
|The role of cancer-associated fibroblasts in MF
|Emmilia Hodak, Tel Aviv, Israel
|ADCC in lymphoma treatment – A spotlight on NK cells?
|Emmanuella Guenova, Lausanne, Switzerland
|SPONSORED LUNCH SYMPOSIUM
|PATHOGENESIS AND ITS TRANSLATION
|Towards a better understanding of the CTCL cellular and molecular landscape
|Muzlifah Haniffa, Newcastle, UK
|Insights into pathogenesis and translational strategies for CTCL
|Michael Girardi, New Haven, CT, USA
|An individualized approach to therapy of advanced MF in the era of personalized medicine
|Oleg Akilov, Pittsburgh, PA, USA
|Indolent vs. aggressive disease
|Patrick M. Brunner, New York, NY, USA
|PATHOGENESIS BASED TREATMENT STRATEGIES
|CTCL: unraveling the mechanisms of long-term disease control
|Adèle de Masson, Paris, France
|New treatment targets
|Martine Bagot, Paris, France
|Therapeutic mechanisms in CTCL: Lessons learnt from photo(chemo)therapy
|Peter Wolf, Graz, Austria
|The association of CTCL with inflammatory skin disorders and its treatments - True causality or misdiagnosis?
|Shamir Geller, New York, NY, USA
|Concluding remarks and awards
The participation for ISDS participants is free of charge. Pre-registration is required and can be made via the ISDS online registration.
In case you would like to attend the symposium only please send an email to firstname.lastname@example.org.